Virtue Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Virtue Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-608	Closed	-$229K	–	365
2023 Q3	$229K	Hold	608	–	–	0.04%	356
2023 Q2	$229K	Sell	608 -58	-9%	-$23.6K	0.04%	353
2023 Q1	$290K	Buy	666 +7	+1%	+$3.28K	0.05%	314
2022 Q4	$277K	Buy	+659	New	+$266K	0.04%	302
2022 Q3	–	Sell	-532	Closed	-$263K	–	261
2022 Q2	$263K	Sell	532 -1,416	-73%	-$737K	0.04%	210
2022 Q1	$1.1M	Sell	1,948 -196	-9%	-$118K	0.17%	148
2021 Q4	$1.62M	Sell	2,144 -18	-0.8%	-$13.5K	0.24%	102
2021 Q3	$1.61M	Sell	2,162 -133	-6%	-$99.6K	0.29%	83
2021 Q2	$1.48M	Buy	2,295 +174	+8%	+$106K	0.3%	89
2021 Q1	$1.21M	Buy	2,121 +146	+7%	+$86.5K	0.29%	110
2020 Q4	$1.15M	Sell	1,975 -513	-21%	-$292K	0.28%	108
2020 Q3	$1.28M	Sell	2,488 -109	-4%	-$55.2K	0.32%	94
2020 Q2	$1.17M	Buy	+2,597	New	+$1.15M	0.27%	112
2020 Q1	–	Sell	-1,451	Closed	-$537K	–	52
2019 Q4	$537K	Buy	+1,451	New	+$512K	0.15%	132

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Virtue Capital Management's BIO Position: Q4 2023 in Review

Virtue Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 608 shares — an estimated $229K sold.

Virtue Capital Management first reported a position in BIO in Q4 2019 and held it in 14 quarters. The position peaked at $1.62M in Q4 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

Virtue Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
Virtue Capital Management sold 608 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $229K.
Virtue Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 14 quarters.
Virtue Capital Management's Bio-Rad Laboratories Class A position peaked at $1.62M in Q4 2021.
484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Virtue Capital Management's 13F filing for Q4 2023, filed 15 Feb 2024.